Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity, a chronic disease characterized by excessive adipose tissue accumulation, represents a critical global health challenge with profound metabolic, inflammatory, and oncogenic implications. To provide a multidisciplinary perspective, this narrative review integrates current literature examining metabolic, immunological, and oncological evidence to outline obesity as a multisystem disorder. Chronic inflammation is examined as a central mediator linking excessive adiposity to insulin resistance, type 2 diabetes, and cancer development, specifically detailing how adipose tissue dysfunction, altered adipokine profiles, and immune cell infiltration drive systemic pathogenesis. Emerging insights into the molecular mechanisms of tumor progression in a metabolically altered environment are highlighted, emphasizing the roles of hyperinsulinemia and dysregulated adipokines like leptin and adiponectin. In addition, the review explores innovative therapeutic strategies for obesity-related cancer, including the use of metformin and therapies targeting insulin-like growth factor 1 receptor and colony-stimulating factor 1 receptor pathways. It also discusses the therapeutic promise of white adipose tissue browning through inductors such as menthol and capsinoids to enhance metabolic homeostasis. Furthermore, hormonal and neural dysregulation of appetite control are addressed. Novel pharmacological treatments targeting appetite, such as glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonists, as well as neuromodulation techniques are discussed as promising avenues for personalized and effective interventions. This comprehensive understanding of obesity's complex nature is crucial for developing novel, integrated approaches to complement traditional diet and exercise strategies.